New hope: targeted pill before surgery for lung cancer
NCT ID NCT03433469
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving the targeted drug osimertinib before surgery can shrink tumors in people with early-stage EGFR-mutant non-small cell lung cancer. About 27 adults with stage I to IIIA disease will receive the drug before their operation. The main goal is to see how many patients have a major reduction in tumor cells after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE I NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California, Davis
Davis, California, 95864, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immunotherapy cocktail shrink inoperable lung tumors?
- Less may be more: smaller lung surgery tested against standard for early cancer
- New combo therapy aims to boost lung cancer fight
- Lung cancer combo therapy trial stopped early
- Lung cancer clues: old data may reveal best Pre-Surgery treatments
- New combo therapy for lung cancer shows promise in early trial